Component
NATHAN 1 NIS-LL plus seven neurophysiological-test composite
NATHAN 1 NIS-LL plus seven neurophysiological-test composite. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
NATHAN 1 did not show a significant ALA effect on its prespecified NIS-LL plus seven-test primary composite at four years (P=0.105).
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ala-research/21775755.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9", "start_char": 0, "end_char": 1839, "text_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9"}
- experimental_model
- NATHAN 1 randomized placebo-controlled trial
- exposure
- ALA 600 mg/day for four years
- limitations
- Primary endpoint and secondary analyses must remain distinct; lack of expected placebo deterioration complicated interpretation.
- nutrient_topic
- Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
- organism
- Human
- plain_language
- The long trial did not meet its main efficacy endpoint.
- primary_references
- [ala-p21775755] Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. (2011). https://pubmed.ncbi.nlm.nih.gov/21775755/ DOI: 10.2337/dc11-0503
- tissue_or_cell_type
- 460 people with mild-to-moderate diabetic polyneuropathy
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1170–1181
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · NATHAN 1 randomized placebo-controlled trial · source_derived_draft · unverified_draft
### ala-nathan1-primary-null NATHAN 1 did not show a significant ALA effect on its prespecified NIS-LL plus seven-test primary composite at four years (P=0.105). Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The long trial did not meet its main efficacy endpoint. organism: Human tissue_or_cell_type: 460 people with mild-to-moderate diabetic polyneuropathy experimental_model: NATHAN 1 randomized placebo-controlled trial limitations: Primary endpoint and secondary analyses must remain distinct; lack of expected placebo deterioration complicated interpretation. exposure: ALA 600 mg/day for four years evidence_span: {"source_cache": "artifacts/ala-research/21775755.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9", "start_char": 0, "end_char": 1839, "text_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9"} [ala-p21775755] Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. (2011). https://pubmed.ncbi.nlm.nih.gov/21775755/ DOI: 10.2337/dc11-0503
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.